A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

Sarah Goldman-Mazur, Artur Jurczyszyn, Jorge J. Castillo, Anna Waszczuk-Gajda, Norbert Grząśko, Jakub Radocha, Max Bittrich, K. Martin Kortüm, Alessandro Gozzetti, Lidia Usnarska-Zubkiewicz, Julio Davila Valls, David S. Jayabalan, Ruben Niesvizky, Julia Kelman, Daniel Coriu, Laura Rosiñol, Łukasz Szukalski, Veronica González-Calle, Maria V. Mateos, Krzysztof JamroziakIwona Hus, Irit Avivi, Yael Cohen, Anna Suska, Aimee Chappell, Deepu Madduri, Saurabh Chhabra, Ariel Kleman, Parameswaran Hari, Michel Delforge, Paweł Robak, Massimo Gentile, Izabela Kozłowska, Stuart L. Goldberg, Jacek Czepiel, Rebecca Silbermann, Adam J. Olszewski, Peter Barth, Gabor Mikala, Chor S. Chim, Monika Długosz-Danecka, Sebastian Grosicki, David H. Vesole

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The t(14;16) translocation, found in 3%-5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real-world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7-18.7), the median progression-free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5-2.4) and 4.1 years (95% CI 3.3-5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05-2.58]), as well as revised International Scoring System (R-ISS) 3 (vs R-ISS 2; HR = 2.59, 95% CI [1.59-4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R-ISS 3 predict poor survival.

Original languageEnglish (US)
Pages (from-to)503-509
Number of pages7
JournalAmerican Journal of Hematology
Volume95
Issue number5
DOIs
StatePublished - May 1 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma'. Together they form a unique fingerprint.

Cite this